Stabilized Outersurface Protein A Fragment as a Lyme Disease Vaccine

Brief Description

Applications

Lyme disease is a tick-borne infection caused by the spirochete Borrelia burgdorferi that can result in damages to joints, cardiovascular and nervous systems. Outsurface protein A (OspA) is a major surface antigen of Borrelia burgdorferi. Anti- OspA mAb has been shown to protect severe combined immunodeficiency mice from clinical symptoms of Lyme disease, suggesting that the Anti- OspA mAb blocks spirochete transmission by binding to OspA. The invention develops site-directed mutations of OspA whose fold conformation is stable.

 

Advantages

The invention develops a stabilized small segment of OspA as a vaccine for Lyme disease. The invention reduces potential side effects of a full length OspA.

 

URV Reference Number: 6-1128

Patent Information:
Title Country Patent No. Issued Date
Altered OSPA of Borrelia burgdorferi United States 8,680,236 3/25/2014
Altered OSPA of Borrelia burgdorferi United States 8,992,936 3/31/2015
Category(s):
Vaccines
For Information, Contact:
Matan Rapoport
Licensing Associate
University of Rochester
585.276.6600
matan.rapoport@rochester.edu
Inventors:
Shohei Koide
Benjamin Luft
John Dunn
Catherine Lawson
Keywords:
Vaccine